Text size: A A A

Introducing a new era in retinal care

JETREA® (ocriplasmin) Intravitreal (IVT) Injection
The first and only pharmacologic treatment for vitreomacular traction, including when associated with macular hole of diameter ≤400 µm1

A single injection of JETREA® resolved vitreomacular traction as compared to placebo1
26.5% of the JETREA® patients achieved resolution at Day 28 (vs 10.1% with placebo)
  • Day 0
  • Day 7
  • Day 14
  • Day 28
  • JETREA® VMT Baseline

    Scans from a single patient in the study. May not be representative of all patients.

  • JETREA® VMT Day 7
    JETREA® VS Placebo
      12, 28
    19.4% 4.8%
  • JETREA® VMT Day 14
    JETREA® VS Placebo
      12, 28
    21.8% 6.9%
  • JETREA® VMT Day 28
    JETREA® VS Placebo
      12, 28
    26.5% 10.1%
26.5% of the JETREA® patients achieved resolution at Day 28 (vs 10.1% with placebo) 26.5% of the JETREA® patients achieved resolution at Day 28 (vs 10.1% with placebo)
See the anatomical difference
26.5% of the JETREA® patients achieved
resolution at Day 28 (vs 10.1% with placebo)2
  • In the set of patients who achieved resolution of vitreomacular traction with JETREA® by Day 28, 72% achieved resolution by Day 728
Impact Calculator 26.5% of patients treated with JETREA® achieved resolution at Day 28 (vs 10.1% with placebo)2
  • In the set of patients who achieved resolution of vitreomacular traction with JETREA® by Day 28, 72% achieved resolution by Day 728

JETREA® (ocriplasmin) Intravitreal (IVT) Injection
Shown to close full-thickness macular hole as compared to placebo1

A single injection of JETREA® helped close macular hole as compared to placebo at Day 281
A single injection of JETREA® helped close macular hole as compared to placebo
at Day 281
40.6% of the JETREA® patients with full-thickness macular hole achieved closure of macular hole ≤400 µm at Day 28 (vs 10.6% with placebo)
  • Day 0
  • Day 7
  • Day 14
  • Day 28
  • JETREA® VMT Baseline

    Scans from a single patient in the study. May not be representative of all patients.

  • JETREA® VMT Day 7
    JETREA® VS Placebo
      12, 28
    28.3% 0%
  • JETREA® VMT Day 14
    JETREA® VS Placebo
      12, 28
    33.0% 2.1%
  • JETREA® VMT Day 28
    JETREA® VS Placebo
      12, 28
    40.6% 10.6%
40.6% of the JETREA® patients with full-thickness macular hole achieved closure of macular hole ≤400 µm at Day 28 (vs 10.6% with placebo) 40.6% of the JETREA® patients with full-thickness macular hole achieved closure of macular hole ≤400 µm at Day 28 (vs 10.6% with placebo)
40.6% of the JETREA® patients with full-thickness macular hole achieved closure of macular hole of diameter ≤400 µm at Day 28 (vs 10.6% with placebo)2
  • In the set of patients who achieved closure of full-thickness macular hole with JETREA® by Day 28, 68% had achieved closure by Day 728
Impact Calculator 40.6% of patients treated with JETREA® with full-thickness macular hole achieved closure of macular hole of diameter ≤400 µm at Day 28 (vs 10.6% with placebo)2
  • In the set of patients who achieved closure of full-thickness macular hole with JETREA® by Day 28, 68% had achieved closure by Day 728

Study design: JETREA® for the treatment of vitreomacular traction (VMT) and macular hole of diameter ≤400 µm 1

Body: Data from two multicenter, randomized, placebo-controlled, double-masked, 6-month studies that investigated the safety and efficacy of a single intravitreal injection of ocriplasmin 125 µg in patients with vitreomacular traction.2

Primary end point: vitreomacular traction resolution at Day 28.2

Secondary end points: Total posterior vitreous detachment and nonsurgical closure of a macular hole at Day 28, avoidance of vitrectomy, and change in best-corrected visual acuity.2

Inclusion criteria: Adult patients with focal vitreomacular adhesion as seen on optical coherence tomography (OCT), and a best-corrected visual acuity of 20/25 or less in the study eye and 20/800 or more in the nonstudy eye according to the Early Treatment Diabetic Retinopathy Study (ETDRS) acuity chart.2

Exclusion criteria: Adult patients with proliferative diabetic retinopathy, neovascular occlusion, aphakia, high myopia, uncontrolled glaucoma, a macular hole greater than 400 µm in diameter, vitreous opacification, lenticular or zonular instability, or a history of retinal detachment in either eye.2

Next: Impact Calculator

Understand the dual-effect mechanism of action of JETREA® (ocriplasmin) Intravitreal (IVT) Injection1,3,4

Dual-effect MOA of JETREA® Dual-effect MOA of JETREA® Dual-effect MOA of JETREA®

JETREA® induces vitreous liquefaction and a clean separation of the vitreous from the vitreoretinal interface.1,3,4

LEARN MORE

Nearly 600 patients worldwide have been treated with the JETREA® injection1

JETREA® product shot JETREA® product shot JETREA® product shot

Learn more about a treatment with an established safety profile.

LEARN MORE

Learn about the impact of vitreomacular traction and macular hole on your patients

Metamorphopsia from a patient perspective Metamorphopsia from a patient perspective Metamorphopsia from a patient perspective

Vitreomacular traction and macular hole often result in visual impairment, particularly central vision loss.8,9

LEARN MORE

Important Safety Information

Indications: JETREA® is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

Dosage: JETREA® must be prepared and administered by a qualified ophthalmologist experienced in intravitreal injections. The recommended dose is 0.125 mg (0.1 mL of the diluted solution) administered by intravitreal injection to the affected eye once as a single dose.

Contraindications: JETREA® is contraindicated for use with patients who are hypersensitive to ocriplasmin or to any of the excipients in JETREA® (mannitol, citric acid, sodium hydroxide and water), or with patients who have active or suspected ocular or periocular infections.

Warnings and Precautions: Post-Injection Monitoring: Intravitreal injections have been associated with intraocular inflammation/infection, intraocular haemorrhage and increased intraocular pressure (IOP). Proper aseptic injection techniques must always be used. Following the intravitreal injection, patients should be monitored for any side effects such as (but not limited to) intraocular inflammation/infection and elevation in IOP. Other Warnings and Precautions: Administration of JETREA® to both eyes concurrently has not been studied, and is not recommended. Repeated administration of JETREA® in the same eye has not been studied, and is not recommended. There are no clinical data on the concomitant use of ocriplasmin with VEGF-inhibitors. JETREA® has not been studied in patients with large diameter macular holes (>400 microns), high myopia (>8 dioptre spherical correction or axial length >28 mm), aphakia, history of rhegmatogenous retinal detachment, lens zonule instability, recent ocular surgery or intraocular injection (including laser therapy), proliferative diabetic retinopathy, ischaemic retinopathies, retinal vein occlusions, exudative age-related macular degeneration (AMD) and vitreous haemorrhage; treatment is not recommended in these patients. The potential for lens subluxation or phacodonesis cannot be ruled out. There is limited experience in patients with non-proliferative diabetic retinopathy or in patients with a history of uveitis or significant eye trauma; caution should be exercised when treating such patients. The effect of ocriplasmin (particularly in inducing resolution of vitreomacular adhesion (VMA) or causing total posterior vitreous detachment (PVD) is reduced in subjects with an epiretinal membrane (ERM) or a diameter of VMA >1500 microns. Due to a potential increase in tractional forces, there is a risk of occurrence of new or enlarged macular holes. There is a risk for a significant, but transient loss of visual acuity during the first week after the injection; patients should be monitored appropriately.

Interactions: No formal interaction studies have been conducted.

Undesirable Effects: In the JETREA® clinical studies, all adverse reactions were ocular. Most of the adverse reactions occurred within the first week after the injection. The majority of these reactions were non-serious, mild in intensity and resolved within 2 to 3 weeks. The incidence of serious adverse reactions that occurred in all clinical studies was 2.2% in JETREA® treated patients and 2.4% in placebo-controlled patients. Very common (≥1/10) adverse reactions are: vitreous floaters, eye pain, and conjunctival haemorrhage. Common (≥1/100 to <1/10) adverse reactions are: visual acuity reduced, visual impairment, vision blurred, retinal haemorrhage, vitreous haemorrhage, retinal tear, retinal detachment, intraocular pressure increased,macular hole, macular degeneration, retinal degeneration, macular oedema, retinal oedema, retinal pigment epitheliopathy, metamorphopsia, vitreous adhesions, conjunctival oedema, eyelid oedema, vitritis, anterior chamber cell, anterior chamber flare, iritis, photopsia, conjunctival hyperaemia, ocular hyperaemia, vitreous detachment, retinogram abnormal, eye irritation, dry eye, foreign body sensation in eyes, eye pruritus, ocular discomfort, photophobia, and chromatopsia. Uncommon (≥1/1,000 to <1/100) are: transient blindness, lens subluxation, scotoma, visual field defect, diplopia, hyphaema, miosis, pupils unequal, corneal abrasion, anterior chamber inflammation, eye inflammation, and conjunctival irritation.

Click here to review the JETREA® Summary of Product Characteristics.